AstraZeneca divests global rights to Movantik
25 February 2020 07:00 GMT AstraZeneca divests global rights to Movantik License to RedHill Biopharma supports AstraZeneca's focus on main therapy areas AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: "This divestment supports our strategy to